Key Takeaways
- • Claret Capital Partners closed its fourth European growth debt fund at €575 million, exceeding its €500 million target and bringing total capital raised since inception to €1.3 billion with €1.5 billion deployed across 210 companies.
- • Fund IV has already deployed 32 percent of capital across 27 portfolio companies in technology, life sciences, and impact sectors, including venture debt positions in Billie (b2b BNPL), Cinclus Pharma, Proda (commercial real estate software), Inventiva (clinical-stage biotech), and Surfe (b2b sales intelligence).
- • Managing partner David Bateman highlighted significant demand for venture debt capital in European growth financing, noting that companies in dual-use technology, artificial intelligence, and deep tech are increasingly selecting venture debt to reduce founder dilution compared to traditional venture capital.
- • The fund close reflects broader market momentum in European venture and growth financing, where venture debt has become a complementary financing tool as growth companies face capital demands and sensitivity to market conditions distinct from prior market cycles.
Summary
Claret Capital Partners has successfully closed its fourth European growth debt fund at €575 million, surpassing its initial €500 million fundraising target. The oversubscribed close represents continued institutional confidence in the London-based venture debt manager and reflects strong capital availability for growth-stage financing in Europe.
The fund has already begun capital deployment, with 32 percent invested across 27 venture and growth companies operating primarily in technology, life sciences, and impact sectors. Portfolio investments include notable positions in Billie, a business-to-business buy-now-pay-later platform; Cinclus Pharma, a clinical-stage pharmaceutical developer; Proda, a commercial real estate software provider; Inventiva, a clinical-stage biotech company; and Surfe, a business-to-business sales intelligence platform. This diversified sector exposure aligns with emerging growth financing trends in Europe.
The Fund IV close brings Claret's total capital raised since inception to €1.3 billion, with €1.5 billion now deployed across 210 companies firm-wide. According to David Bateman, managing partner at Claret Capital Partners, the fund closure occurs during a period of robust demand for venture and growth financing capital in Europe. Bateman noted that companies increasingly seek venture debt products to reduce dilution to early-stage investors, positioning debt financing as a strategic complement to traditional venture capital rather than a substitute. He highlighted that capital allocation is increasingly concentrated in dual-use technology, artificial intelligence, and deep tech sectors—areas that exhibit distinct risk profiles and financing behavior compared to earlier market cycles.
The successful close underscores the growing institutional recognition of venture debt as a specialized asset class within European alternative credit markets, supporting growth companies through capital-intensive development phases while preserving founder equity ownership.
The fund has already begun capital deployment, with 32 percent invested across 27 venture and growth companies operating primarily in technology, life sciences, and impact sectors. Portfolio investments include notable positions in Billie, a business-to-business buy-now-pay-later platform; Cinclus Pharma, a clinical-stage pharmaceutical developer; Proda, a commercial real estate software provider; Inventiva, a clinical-stage biotech company; and Surfe, a business-to-business sales intelligence platform. This diversified sector exposure aligns with emerging growth financing trends in Europe.
The Fund IV close brings Claret's total capital raised since inception to €1.3 billion, with €1.5 billion now deployed across 210 companies firm-wide. According to David Bateman, managing partner at Claret Capital Partners, the fund closure occurs during a period of robust demand for venture and growth financing capital in Europe. Bateman noted that companies increasingly seek venture debt products to reduce dilution to early-stage investors, positioning debt financing as a strategic complement to traditional venture capital rather than a substitute. He highlighted that capital allocation is increasingly concentrated in dual-use technology, artificial intelligence, and deep tech sectors—areas that exhibit distinct risk profiles and financing behavior compared to earlier market cycles.
The successful close underscores the growing institutional recognition of venture debt as a specialized asset class within European alternative credit markets, supporting growth companies through capital-intensive development phases while preserving founder equity ownership.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.